Core Viewpoint - The approval of Lidocaine Gel Patch (brand name: Debain) by the National Medical Products Administration marks a significant milestone for Tide Pharmaceutical in the treatment of diabetic peripheral neuropathic pain (DPNP) [1] Company Overview - Tide Pharmaceutical has over 20 years of experience in transdermal formulation technology, focusing on this core area to build a leading modern transdermal technology platform and product matrix in China [1] - The company has successfully launched several products, including: - Fluorobuprofen Gel Patch (Debian) in 2010, capturing 90% of the domestic hospital external analgesic market with annual sales exceeding 30 billion [1] - Debain in 2018, filling a gap in external treatment for postherpetic neuralgia [1] - Suledar, an Alzheimer's treatment patch, recognized upon its initial launch in 2024 [1] - Deritro, a cough and asthma relief patch, expected to launch in 2025 [1] - Recently approved Rotigotine Parkinson's patch (Rofidin), enhancing the company's presence in the neurological field [1] Product Development Strategy - Tide Pharmaceutical plans to launch 14 transdermal delivery products by 2030, continuously improving its product layout through a strategy of "star-led, tiered collaboration" [1]

Group 1 - Beijing Tide Pharmaceutical has launched its self-developed terbutaline patch (Derytuo) across major e-commerce platforms and offline pharmacies, marking it as the first domestically produced terbutaline patch in China [1] - The global transdermal drug delivery market is expanding at a compound annual growth rate (CAGR) of 5%, driven by an aging population and increasing chronic disease burden [1][3] Group 2 - The terbutaline patch utilizes innovative sustained-release technology to control the permeation rate, allowing for continuous absorption through the skin, thus overcoming traditional treatment limitations [2] - The patch is approved for patients aged 9 and above, with plans to extend its use to children under 9, potentially opening up the pediatric market [2] Group 3 - The global transdermal patch market is projected to grow from $7.88 billion in 2023 to $10.33 billion by 2029, with a CAGR of approximately 5% from 2024 to 2029 [3] - Beijing Tide has developed a comprehensive technology platform covering gel patches, hot melt adhesive patches, transdermal patches, and microneedle patches, establishing a fully controllable supply chain from raw materials to finished products [3][4] Group 4 - The company has successfully launched five patch products, including the first domestic non-steroidal anti-inflammatory gel patch, which has gained recognition among healthcare providers and patients [4] - With an annual production capacity of 330 million patches, Beijing Tide is accelerating the transformation of laboratory results into clinical value through partnerships with e-commerce platforms and educational content [4]